𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities

✍ Scribed by M. Barberi-Heyob; B. Weber; J. L. Merlin; C. Dittrich; E. A. Bruijn; E. Luporsi; F. Guillemin

Publisher
Springer
Year
1995
Tongue
English
Weight
692 KB
Volume
37
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The eastern cooperative oncology group e
The eastern cooperative oncology group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer
✍ Geoffrey Falkson; Rebecca S. Gelman; Douglass C. Tormey; Frank J. Cummings; Paul πŸ“‚ Article πŸ“… 1985 πŸ› John Wiley and Sons 🌐 English βš– 497 KB πŸ‘ 3 views

Data on 162 women (90 premenopausal and 72 postmenopausal) with metastatic breast cancer randomized to receive cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF) on two Eastern Cooperative Oncology Group (ECOG) protocols were analyzed. Twenty-three percent had complete remission; 39

Plasma levels of soluble CD105 correlate
Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer
✍ Chenggang Li; Baoqiang Guo; Phillip B. Wilson; Alan Stewart; Ged Byrne; Nigel Bu πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 French βš– 72 KB πŸ‘ 2 views

CD105 (endoglin), a receptor for transforming growth factor (TGF) ␀1 and ␀3 in vascular endothelial cells, is highly up-regulated in blood vessels of tissues where neovascularisation occurs. It modulates endothelial-mesenchymal signalling and is essential for angiogenesis. Indeed, CD105 knockout mic

A randomized multicenter trial of cyclop
A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer
✍ John M. Bennett; Patrick Byrne; Ajit Desai; Charles White; Ronald DeConti; Charl πŸ“‚ Article πŸ“… 1985 πŸ› Springer US 🌐 English βš– 388 KB

As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF). Seventy-one percent of all patients were post-